Fig. 2 | Leukemia

Fig. 2

From: Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Fig. 2

Overall response rate according to subgroup. This forest plot of data for 70 efficacy-evaluable patients shows the overall response rate according to defined demographic and baseline disease characteristics. The 95% confidence intervals are two-sided Clopper–Pearson estimations. For the category of baseline bone marrow involvement, “No” represents no involvement or not evaluable

Back to article page